Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B-Reference-Cited by-同舟云学术

Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

Published:2023-02-03 Issue:6 Volume:68 Page:2731-2737
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Mateos-Muñoz Beatriz,Buti María,Vázquez Inmaculada Fernández,Conde Marta Hernández,Bernal-Monterde Vanesa,Díaz-Fontenla Fernando,Morillas Rosa María,García-Buey Luisa,Badía Ester,Miquel Mireia,Amador-Navarrete Alberto,Rodríguez-Tajes Sergio,Ramos-Merino Lucía,Madejón Antonio,García-Retortillo Montserrat,Arenas Juan Ignacio,Cabezas Joaquín,Santiago Jesús Manuel González,Fernández-Rodríguez Conrado,Cordero Patricia,Diago Moisés,Mancebo Antonio,Pardo Alberto,Rodríguez Manuel,Hoyas Elena,Moreno Jose Javier,Turnes Juan,Simón Miguel Ángel,Marcos-Fosch Cristina,Calleja Jose Luis,Bañares Rafael,Lens Sabela,Garcia-Samaniego Javier,Crespo Javier,Romero-Gomez Manuel,Gea Francisco,de Santiago Enrique Rodríguez,Moreno Santiago,Albillos Agustin^ORCID

Funder

Universidad de Alcalá

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

https://link.springer.com/content/pdf/10.1007/s10620-022-07817-w.pdf

Reference23 articles.

1. COVID-19 Map. Johns Hopkins Coronavirus Resource Center. [cited 2021 Mar 11]. https://coronavirus.jhu.edu/map.html

2. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.

3. Arribas JR, Polo R, García JG, Palacios R. Esteban Martínez (GeSIDA). 145.

4. del Amo J, Polo R, Moreno S et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy. Ann Intern Med. 2020;173:536–541.

5. Hoffmann C, Casado JL, Härter G et al. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2021;22:372–378.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico study of RNA polymerase inhibitor drugs for Rift Valley fever virus using RdRp protein as the target;Journal of Pharmacy & Pharmacognosy Research;2025-01-01

2. How Does Chronic Hepatitis B Infection Impact on Severity of COVID-19 Infection?;International Journal of Infection;2024-09-01

3. Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B;BMC Infectious Diseases;2023-11-30

4. SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection;Journal of Clinical Virology Plus;2023-11

5. Alleviated symptoms of SARS‐CoV‐2 Omicron variant infection in chronic hepatitis B patients with immune control;Journal of Medical Virology;2023-10